CD7 and lymphoma: It acts as an inhibitory receptor of (TCR) and B-cell receptor (BCR).27,28 CD7 is a transmembrane protein expressed on over 90% of lymphoblastic T-cell leukemias and lymphomas, and ~30% of acute myeloid leukemias,29,30 but it appears to have limited contribution to the development or function of T cells.31 The expression patterns of CD5 and CD7 suggest that they are attractive therapeutic targets for T-cell malignancies.